Affinage

ARID2

AT-rich interactive domain-containing protein 2 · UniProt Q68CP9

Length
1835 aa
Mass
197.4 kDa
Annotated
2026-04-28
61 papers in source corpus 20 papers cited in narrative 21 extracted findings

Mechanistic narrative

Synthesis pass · prose summary of the discoveries below

ARID2 (BAF200) is a defining subunit of the PBAF chromatin-remodeling complex that directs nucleosome remodeling at specific genomic loci to regulate transcription, DNA repair, and cell fate decisions across multiple tissues. As a PBAF specificity factor, ARID2 is required for interferon-responsive gene activation, repression of cell-cycle genes (CCND1, CCNE1) through interaction with E2F1, suppression of EMT via DNMT1 recruitment to the Snail promoter, and maintenance of REST-dependent repressive chromatin; it also activates NEDD4L transcription by recruiting CARM1, thereby promoting JAK2 ubiquitination and suppressing hepatic steatosis (PMID:15985610, PMID:27351279, PMID:32071245, PMID:36396719). ARID2 facilitates homology-directed DNA repair through physical interaction with RAD51 and maintains nucleotide excision repair by enabling XPG recruitment to damage sites, while cooperating with BRD4 to sustain enhancer-promoter loops at DNA repair gene loci (PMID:28381560, PMID:28238438, PMID:35017665). Loss of ARID2 causes embryonic-lethal cardiac defects, impairs hematopoietic stem cell self-renewal, and acts as a tumor suppressor in hepatocellular carcinoma, melanoma, and lung cancer; ARID2 is also a pomalidomide-induced CRL4-CRBN neosubstrate whose degradation de-represses MYC in multiple myeloma (PMID:25299188, PMID:29482581, PMID:32958952, PMID:33333124).

Mechanistic history

Synthesis pass · year-by-year structured walk · 13 steps
  1. 2005 High

    Establishing ARID2 as a PBAF-specific subunit resolved how SWI/SNF subcomplexes achieve target-gene selectivity, showing that PBAF and BAF remodel distinct promoter sets and that ARID2 is required specifically for interferon-responsive gene transcription.

    Evidence Biochemical purification of PBAF/BAF, in vitro transcription assays, and RNAi-mediated gene expression profiling

    PMID:15985610

    Open questions at the time
    • No genome-wide binding profile for ARID2-containing PBAF
    • Mechanism by which ARID2 confers locus selectivity undefined
    • Whether ARID2 contributes to non-transcriptional PBAF functions unknown
  2. 2014 High

    Demonstrating that ARID2 knockout causes embryonic lethality with cardiac defects established ARID2 as essential for heart morphogenesis and coronary vasculogenesis, extending its role beyond transcription regulation to organ development.

    Evidence Constitutive and conditional knockout mice with histological and immunofluorescence analysis of cardiac structures

    PMID:25299188

    Open questions at the time
    • Target genes mediating the cardiac phenotype not identified
    • Whether the cardiac role is PBAF-dependent or PBAF-independent not determined
  3. 2016 Medium

    Identification of a physical ARID2–E2F1 interaction that reduces E2F1/Pol II occupancy at CCND1 and CCNE1 promoters revealed how ARID2 directly restrains G1/S progression in hepatoma cells, linking chromatin remodeling to cell-cycle control.

    Evidence Co-immunoprecipitation, ChIP, reporter assays, and xenograft models in hepatoma cells

    PMID:27351279

    Open questions at the time
    • Whether ARID2 remodels nucleosomes at E2F1-occupied promoters or blocks E2F1 binding through steric competition is unresolved
    • Generalizability beyond hepatoma not tested
  4. 2017 High

    Discovery that ARID2 physically interacts with RAD51 and facilitates its recruitment to DSBs, alongside identification of a BRG1-independent PBAF variant, established ARID2 as a direct participant in homology-directed DNA repair and revealed unexpected PBAF compositional heterogeneity.

    Evidence Co-IP, immunofluorescence, HR reporter assay, clonogenic survival, and biochemical fractionation

    PMID:28381560

    Open questions at the time
    • How ARID2 promotes RAD51 loading mechanistically (chromatin remodeling vs. direct scaffolding) unclear
    • Function of the BRG1-independent PBAF variant uncharacterized
  5. 2017 High

    Showing that ARID2 knockout prevents XPG accumulation at UV/carcinogen-induced damage sites linked PBAF-mediated chromatin remodeling to nucleotide excision repair and explained the hypermutation phenotype of ARID2-deficient HCC.

    Evidence CRISPR knockout in HCC cells, NER functional assay, immunofluorescence for XPG recruitment with multiple DNA-damage agents

    PMID:28238438

    Open questions at the time
    • Whether ARID2 remodels nucleosomes at damage sites to expose DNA for XPG or acts through an indirect mechanism unknown
    • Relationship between NER and HR roles of ARID2 not addressed
  6. 2018 High

    Conditional knockout studies in hematopoietic lineages revealed ARID2 is essential for HSC self-renewal and erythropoiesis and acts as a tumor suppressor that restrains MLL-AF9-driven leukemogenesis, broadening its developmental role to blood cell homeostasis.

    Evidence Multiple Cre-driver knockouts, bone marrow transplantation, RNA-seq, and MLL-AF9 leukemia mouse model

    PMID:29482581

    Open questions at the time
    • Direct transcriptional targets of ARID2 in HSCs not defined by ChIP
    • Whether PBAF integrity is required for the hematopoietic phenotype not tested
  7. 2019 Medium

    Identification of HBV core protein binding to the ARID2 C-terminus, disrupting PBAF stability and suppressing IFITM1 transcription, provided a viral mechanism for innate immune evasion through PBAF subversion.

    Evidence Yeast two-hybrid, Co-IP in multiple hepatocyte lines, transcriptional reporter assays

    PMID:31075894

    Open questions at the time
    • Global impact of HBc on PBAF complex composition not characterized
    • In vivo relevance of HBc–ARID2 interaction during HBV infection not demonstrated
  8. 2020 High

    Demonstration that ARID2 recruits DNMT1 to the Snail promoter to methylate and silence it revealed a chromatin-remodeler–DNA-methyltransferase partnership that suppresses EMT and metastasis in HCC, with the C2H2 zinc finger domain being essential.

    Evidence Co-IP, ChIP-bisulfite sequencing, domain mutagenesis, and in vivo metastasis models

    PMID:32071245

    Open questions at the time
    • Whether ARID2-DNMT1 cooperation is genome-wide or promoter-specific unknown
    • Structural basis of the zinc finger requirement not resolved
  9. 2020 High

    Identification of ARID2 as a pomalidomide-induced CRL4-CRBN neosubstrate, degraded in a BRD7-dependent manner, uncovered a pharmacological mechanism by which immunomodulatory drugs de-repress MYC through PBAF destabilization in multiple myeloma.

    Evidence Proteomics, Co-IP, CRISPR knockout, protein stability assays, and transcriptional profiling in myeloma cells

    PMID:32958952

    Open questions at the time
    • Structural basis for pomalidomide-induced CRBN–ARID2 interaction not determined
    • Whether ARID2 degradation is therapeutically beneficial or detrimental in myeloma not established
  10. 2020 Medium

    Finding that ARID2 loss in melanoma upregulates STAT1 and T-cell-attracting chemokines, sensitizing tumors to anti-PD-L1 therapy, reframed ARID2 deficiency as a potential immunotherapy biomarker rather than solely a loss-of-function event.

    Evidence CRISPR knockout in melanoma, in vivo anti-PD-L1 treatment, flow cytometry, transcriptional analysis

    PMID:33333124

    Open questions at the time
    • Whether STAT1 upregulation is a direct consequence of altered PBAF chromatin remodeling not shown
    • Applicability to other tumor types unknown
  11. 2022 High

    Revealing that ARID2 recruits CARM1 to the NEDD4L promoter to activate NEDD4L transcription, driving JAK2 ubiquitination and suppressing JAK2-STAT5-PPARγ signaling, established a chromatin-remodeler–methyltransferase–ubiquitin ligase cascade controlling hepatic lipid metabolism.

    Evidence Liver-specific Arid2 knockout mice, ChIP, Co-IP, ubiquitination assay, high-fat diet model with pharmacological JAK2 inhibition rescue

    PMID:36396719

    Open questions at the time
    • Whether CARM1 recruitment requires PBAF remodeling activity not distinguished
    • Whether this pathway operates in non-hepatic tissues unknown
  12. 2022 Medium

    Demonstration that ARID2 and BRD4 co-maintain enhancer-promoter loops at BRCA1, RAD51, and 53BP1 loci revealed a synthetic lethal interaction exploitable therapeutically, showing ARID2 deficiency plus BRD4 inhibition catastrophically impairs both HR and NHEJ.

    Evidence High-throughput drug screening, CRISPR KO, ChIP, chromosome conformation assay, and DNA damage assays in HCC cells

    PMID:35017665

    Open questions at the time
    • Whether ARID2 directly stabilizes 3D chromatin loops or acts through transcriptional regulation of loop-forming factors not resolved
    • Applicability of synthetic lethality in clinical settings untested
  13. 2022 Medium

    Identification of USP2 as a deubiquitinase that physically interacts with and stabilizes ARID2 protein provided the first evidence of regulated ARID2 turnover outside the CRBN-dependent degradation pathway.

    Evidence Co-IP, immunofluorescence colocalization, CHX chase, and ubiquitination assays in lung cancer cells

    PMID:36567903

    Open questions at the time
    • The E3 ligase responsible for basal ARID2 ubiquitination not identified
    • In vivo significance of USP2-mediated ARID2 stabilization not demonstrated

Open questions

Synthesis pass · forward-looking unresolved questions
  • Major unresolved questions include the structural basis for ARID2-mediated locus selectivity within PBAF, the full complement of ARID2-dependent genomic targets across tissues, and whether ARID2's DNA-repair and transcriptional functions are mechanistically separable.
  • No high-resolution structure of ARID2 within PBAF complex
  • No genome-wide ChIP-seq map of ARID2 across multiple normal tissues
  • Separation-of-function mutations distinguishing transcription from DNA repair roles not established

Mechanism profile

Synthesis pass · controlled-vocabulary classification · explore literature graph →
Molecular activity
GO:0140110 transcription regulator activity 4 GO:0003677 DNA binding 2 GO:0140097 catalytic activity, acting on DNA 2
Localization
GO:0005634 nucleus 5 GO:0005694 chromosome 3
Pathway
R-HSA-4839726 Chromatin organization 4 R-HSA-74160 Gene expression (Transcription) 4 R-HSA-1643685 Disease 3 R-HSA-73894 DNA Repair 3 R-HSA-1266738 Developmental Biology 2 R-HSA-168256 Immune System 2 R-HSA-1640170 Cell Cycle 1
Partners
BAF180BRD7BRG1CARM1DNMT1E2F1RAD51USP2
Complex memberships
CRL4-CRBN (as neosubstrate)PBAF (SWI/SNF)

Evidence

Reading pass · 21 per-paper findings extracted from the source corpus
Year Finding Method Journal Conf PMIDs
2005 ARID2 (BAF200) is a specificity subunit of the PBAF chromatin-remodeling complex (SWI/SNF family) required for selective transcriptional activation of interferon-responsive genes; PBAF and BAF regulate distinct gene sets, and BAF200 is required for PBAF-specific transcription but not BAF-specific transcription. Biochemical purification of PBAF/BAF complexes, in vitro transcription assays with nuclear receptors, RNAi knockdown with gene expression profiling Genes & development High 15985610
2014 ARID2 (BAF200) is required for heart morphogenesis and coronary artery development in vivo; BAF200 knockout mice are embryonic lethal with cardiac defects including thin myocardium, ventricular septum defect, and defective migration/differentiation of subepicardial venous cells into arterial endothelial cells. Conditional/constitutive knockout mouse model, histological and immunofluorescence analysis of cardiac phenotype PloS one High 25299188
2016 ARID2 physically interacts with E2F1 and decreases binding of E2F1/RNA Pol II to the promoters of CCND1 (cyclin D1) and CCNE1 (cyclin E1), thereby repressing their expression and retarding G1/S cell cycle progression in hepatoma cells. Co-immunoprecipitation, ChIP assay, reporter assays, gain/loss-of-function in hepatoma cell lines and xenograft models Oncotarget Medium 27351279
2017 ARID2 (Baf200) promotes homology-directed DNA double-strand break (DSB) repair by facilitating RAD51 recruitment to DSBs; Baf200 and RAD51 physically interact through C-terminal sequences in both proteins. Baf200 forms at least two distinct PBAF complexes: one canonical PBAF containing BRG1 and one containing BAF180 but not BRG1. Cytological and biochemical assays (Co-IP, immunofluorescence, HR reporter assay, clonogenic survival after DNA damage), biochemical fractionation The Journal of biological chemistry High 28381560
2017 ARID2 knockout in HCC cells disrupts nucleotide excision repair (NER) by preventing XPG from accumulating at DNA damage sites induced by UV, benzo[a]pyrene, and FeCl3, leading to hypermutation susceptibility. CRISPR/Cas9 knockout, gene expression profiling, NER functional assay, immunofluorescence for XPG recruitment Journal of hepatology High 28238438
2019 HBV core protein (HBc) physically interacts with the C-terminal domain of BAF200 (ARID2), disrupting PBAF complex stability and suppressing IFITM1 transcription; basal IFITM1 expression depends on BAF200 rather than the JAK-STAT1 pathway. Yeast two-hybrid screen, Co-immunoprecipitation in 293T/HepG2/HepG2-NTCP cells, transcriptional reporter assays Viruses Medium 31075894
2020 ARID2 suppresses epithelial-mesenchymal transition (EMT) in HCC by recruiting DNMT1 to the Snail promoter, increasing promoter methylation and inhibiting Snail transcription; ARID2 mutants with disrupted C2H2 zinc finger domain lose this metastasis-suppressor function. Co-IP, ChIP-bisulfite sequencing, bisulfite sequencing, loss/gain-of-function in HCC cells and mouse metastasis models, domain mutagenesis Proceedings of the National Academy of Sciences of the United States of America High 32071245
2020 ARID2 is a pomalidomide-induced neosubstrate of the CRL4CRBN E3 ubiquitin ligase complex; pomalidomide induces ARID2 degradation more potently than lenalidomide. BRD7 (another PBAF subunit) is required for pomalidomide-induced ARID2 degradation. ARID2 regulates transcription of MYC and other pomalidomide target genes. Proteomics, Co-IP, CRISPR/KO, overexpression, protein stability assays, transcriptional profiling in multiple myeloma cells Nature chemical biology High 32958952
2020 ARID2 deficiency in melanoma leads to STAT1 upregulation, which increases expression of T-cell-attracting chemokines (CXCL9, CXCL10, CCL5), sensitizing tumors to anti-PD-L1 immune checkpoint inhibitors. ARID2 CRISPR knockout in melanoma, mouse tumor models with anti-PD-L1 treatment, flow cytometry for CD8+ T cells, transcriptional analysis The Journal of investigative dermatology Medium 33333124
2020 ARID2 haploinsufficiency is associated with enhanced RAS-MAPK (ERK1/2 phosphorylation) activity through reduced expression of IFITM1, which interacts with caveolin-1 (CAV-1) to inhibit ERK activation; demonstrated in patient iPSCs and Arid2 haploinsufficient mouse models. shRNA knockdown in HeLa cells, patient-derived iPSC neuronal differentiation, CRISPR-generated haploinsufficient mouse model, phospho-ERK western blotting, behavioral tests Journal of medical genetics Medium 33051312
2022 ARID2 mitigates hepatic steatosis by promoting ubiquitination and degradation of JAK2 via the E3 ligase NEDD4L, thereby repressing the JAK2-STAT5-PPARγ signaling axis; ARID2 recruits the methyltransferase CARM1 to the NEDD4L promoter, increasing H3R17me2a and activating NEDD4L transcription. Liver-specific Arid2 knockout mice, ChIP assay, Co-IP, ubiquitination assay, high-fat diet model, pharmacological JAK2 inhibition rescue Cell death and differentiation High 36396719
2022 USP2 deubiquitinase physically interacts with ARID2 and reduces its ubiquitin-mediated proteasomal degradation, thereby stabilizing ARID2 protein in lung cancer cells. Co-immunoprecipitation, immunofluorescence colocalization, CHX chase assay, ubiquitination assay BioMed research international Medium 36567903
2022 ARID2 and BRD4 synergistically maintain transcriptional enhancer-promoter loops at BRCA1, RAD51, and 53BP1 loci; combined ARID2 deficiency and BRD4 inhibition synergistically impairs homologous recombination and NHEJ, causing DSB accumulation and synthetic lethality in HCC cells. High-throughput drug screening, CRISPR KO, ChIP, chromosome conformation assay, DNA damage functional assays (γH2AX, RAD51 foci) Oncogene Medium 35017665
2018 ARID2 (Baf200) is required for hematopoietic stem cell (HSC) self-renewal and differentiation; conditional Baf200 knockout impairs long-term HSC reconstitution, erythropoiesis, and accelerates MLL-AF9-driven leukemia, with transcriptomes showing altered expression of erythropoiesis/hematopoiesis genes. Tissue-specific Cre-lox knockout (Tie2-Cre, Vav-iCre, Mx1-Cre), bone marrow transplantation, RNA-seq, leukemia mouse model Journal of hematology & oncology High 29482581
2017 HBV X protein (HBx) suppresses ARID2 transcription through downregulation of ATOH1; ATOH1 binding elements in the ARID2 promoter (nt-1040/nt-601) are required for this regulation, as mutation of ATOH1 binding sites partially abolishes HBx-triggered ARID2 repression. Reporter assays, promoter deletion analysis, ectopic ATOH1 expression, site-directed mutagenesis, Western blotting, HBV transgenic mice Cancer science Medium 28498550
2018 The ARID domain of human BAF200 (ARID2) adopts a defined secondary structure and has the potential to bind DNA sequences; NMR chemical shift assignments establish its fold as an ARID-type domain. NMR spectroscopy (backbone 1H, 13C, 15N chemical shift assignment) Biomolecular NMR assignments Low 30535613
2016 ARID2 represses CD44 promoter activity and protein expression in HCC cells; overexpression of ARID2 inhibits migration and invasion of HepG2 and Huh7 cells and restricts subcutaneous tumor growth in nude mice. Dual luciferase reporter assay, Western blot, cell migration assay, xenograft mouse model Zhonghua gan zang bing za zhi Low 27095763
2024 PBAF complex (defined by ARID2) co-occupies repressive chromatin regions with PRC2 and facilitates REST transcription factor occupancy at these loci; loss of ARID2 disrupts PBAF complex integrity, impairs REST binding, and leads to upregulation of synaptic/neuronal transcripts in melanoma. ChIP-seq, ATAC-seq, CUT&RUN, ARID2 CRISPR knockout, time-resolved chromatin remodeling assays in melanoma cells and melanocytes bioRxivpreprint Medium
2025 Arid2 is required for follicular B cell differentiation and germinal center responses in vivo; Arid2 deletion impairs stage-specific gene expression programs including B cell receptor signaling, and reduces IgG antibody production after immunization. Conditional knockout mice (Mb1-Cre, CD19-Cre), bone marrow transplantation, RNA-seq of isolated B cell populations, immunization experiments, flow cytometry bioRxivpreprint Medium 41256460
2021 ARID2 deficiency in lung cancer impairs DNA repair and alters chromatin structure, promoting proliferation and metastasis in vitro and in vivo; ARID2 loss increases sensitivity to DNA-damaging chemotherapy agents. Targeted sequencing of patient cohort, protein expression analysis, ARID2 KO/KD functional experiments (proliferation, migration, invasion assays), in vivo tumor models, chromatin structure analysis Oncogene Medium 33742126
2024 In TFE3-rearranged RCC, PRCC-TFE3 fusion directly binds and upregulates ERBB3 expression; ARID2 knockout further enhances this effect and activates MAPK and ERBB3 signaling pathways, with ARID2-KO cells showing heightened sensitivity to ERBB3 inhibition. ChIP assay (PRCC-TFE3 binding to ERBB3), CRISPR KO, transcriptomic analysis, in vitro/in vivo tumor models, pharmacological inhibition Current issues in molecular biology Medium 39727945

Source papers

Stage 0 corpus · 61 papers · ranked by NIH iCite citations
Year Title Journal Citations PMID
2011 Inactivating mutations of the chromatin remodeling gene ARID2 in hepatocellular carcinoma. Nature genetics 337 21822264
2005 PBAF chromatin-remodeling complex requires a novel specificity subunit, BAF200, to regulate expression of selective interferon-responsive genes. Genes & development 191 15985610
2015 Long Noncoding RNA Arid2-IR Is a Novel Therapeutic Target for Renal Inflammation. Molecular therapy : the journal of the American Society of Gene Therapy 117 25743111
2014 Exome sequencing reveals frequent inactivating mutations in ARID1A, ARID1B, ARID2 and ARID4A in microsatellite unstable colorectal cancer. International journal of cancer 101 24382590
2020 Chromatin remodeling factor ARID2 suppresses hepatocellular carcinoma metastasis via DNMT1-Snail axis. Proceedings of the National Academy of Sciences of the United States of America 89 32071245
2020 ARID2 is a pomalidomide-dependent CRL4CRBN substrate in multiple myeloma cells. Nature chemical biology 75 32958952
2019 MiR-155-5p promotes oral cancer progression by targeting chromatin remodeling gene ARID2. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 72 31918270
2012 Recurrent inactivating mutations of ARID2 in non-small cell lung carcinoma. International journal of cancer 65 23047306
2021 ARID1A, ARID1B, and ARID2 Mutations Serve as Potential Biomarkers for Immune Checkpoint Blockade in Patients With Non-Small Cell Lung Cancer. Frontiers in immunology 57 34512623
2017 ARID2 modulates DNA damage response in human hepatocellular carcinoma cells. Journal of hepatology 55 28238438
2017 Heterozygosity for ARID2 loss-of-function mutations in individuals with a Coffin-Siris syndrome-like phenotype. Human genetics 54 28124119
2015 Mutations in ARID2 are associated with intellectual disabilities. Neurogenetics 53 26238514
2016 MicroRNA-155 promotes tumor growth of human hepatocellular carcinoma by targeting ARID2. International journal of oncology 50 27035278
2011 ARID2: a new tumor suppressor gene in hepatocellular carcinoma. Oncotarget 47 22095441
2016 Chromatin remodeling gene ARID2 targets cyclin D1 and cyclin E1 to suppress hepatoma cell progression. Oncotarget 36 27351279
2021 ARID2 deficiency promotes tumor progression and is associated with higher sensitivity to chemotherapy in lung cancer. Oncogene 32 33742126
2020 ARID2 Deficiency Correlates with the Response to Immune Checkpoint Blockade in Melanoma. The Journal of investigative dermatology 31 33333124
2018 The chromatin remodeling subunit Baf200 promotes normal hematopoiesis and inhibits leukemogenesis. Journal of hematology & oncology 31 29482581
2014 BAF200 is required for heart morphogenesis and coronary artery development. PloS one 31 25299188
2017 The chromatin-remodeling subunit Baf200 promotes homology-directed DNA repair and regulates distinct chromatin-remodeling complexes. The Journal of biological chemistry 30 28381560
2015 Loss of ARID1A, ARID1B, and ARID2 Expression During Progression of Gastric Cancer. Anticancer research 29 26637902
2015 miR-208-3p promotes hepatocellular carcinoma cell proliferation and invasion through regulating ARID2 expression. Experimental cell research 28 26169693
2020 Exome sequencing identifies ARID2 as a novel tumor suppressor in early-onset sporadic rectal cancer. Oncogene 27 33262464
2018 Early growth response protein-1 upregulates long noncoding RNA Arid2-IR to promote extracellular matrix production in diabetic kidney disease. American journal of physiology. Cell physiology 25 30462533
2021 Targeting HSPA1A in ARID2-deficient lung adenocarcinoma. National science review 20 34858604
2020 ARID2 Chromatin Remodeler in Hepatocellular Carcinoma. Cells 20 32977645
2019 Human Hepatitis B Virus Core Protein Inhibits IFNα-Induced IFITM1 Expression by Interacting with BAF200. Viruses 18 31075894
2022 BRD4 inhibition induces synthetic lethality in ARID2-deficient hepatocellular carcinoma by increasing DNA damage. Oncogene 17 35017665
2020 Arid2-IR promotes NF-κB-mediated renal inflammation by targeting NLRC5 transcription. Cellular and molecular life sciences : CMLS 17 33090288
2017 HBx protein-mediated ATOH1 downregulation suppresses ARID2 expression and promotes hepatocellular carcinoma. Cancer science 17 28498550
2020 Arid2 regulates hematopoietic stem cell differentiation in normal hematopoiesis. Experimental hematology 16 33346030
2017 Confirmation of an ARID2 defect in SWI/SNF-related intellectual disability. American journal of medical genetics. Part A 16 28884947
2017 microRNA‑96 regulates the proliferation of nucleus pulposus cells by targeting ARID2/AKT signaling. Molecular medicine reports 16 28944851
2022 ARID2 mitigates hepatic steatosis via promoting the ubiquitination of JAK2. Cell death and differentiation 15 36396719
2021 CREB1 acts via the miR‑922/ARID2 axis to enhance malignant behavior of liver cancer cells. Oncology reports 14 33786634
2019 Patient with anomalous skin pigmentation expands the phenotype of ARID2 loss-of-function disorder, a SWI/SNF-related intellectual disability. American journal of medical genetics. Part A 13 30838730
2018 Extending the clinical and genetic spectrum of ARID2 related intellectual disability. A case series of 7 patients. European journal of medical genetics 13 29698805
2022 USP2 Inhibits Lung Cancer Pathogenesis by Reducing ARID2 Protein Degradation via Ubiquitination. BioMed research international 12 36567903
2022 Concomitant novel ALK-SSH2, EML4-ALK and ARID2-ALK, EML4-ALK double-fusion variants and confer sensitivity to crizotinib in two lung adenocarcinoma patients, respectively. Diagnostic pathology 11 35144623
2022 SIS3 Alleviates Cisplatin-Induced Acute Kidney Injury by Regulating the LncRNA Arid2-IR-Transferrin Receptor Pathway. Kidney & blood pressure research 9 36315994
2020 Association between ARID2 and RAS-MAPK pathway in intellectual disability and short stature. Journal of medical genetics 9 33051312
2024 ARID2 mutations may relay a distinct subset of cutaneous melanoma patients with different outcomes. Scientific reports 8 38341515
2022 ARID2, a Rare Cause of Coffin-Siris Syndrome: A Clinical Description of Two Cases. Frontiers in pediatrics 8 35813374
2023 ARID2, a rare cause of Coffin-Siris syndrome: A novel microdeletion at 12q12q13.11 causing severe short stature and literature review. American journal of medical genetics. Part A 7 36756859
2020 Long non-coding RNA Arid2-IR affects advanced glycation end products-induced human retinal endothelial cell injury by binding to Smad3. International ophthalmology 7 31912402
2024 ARID2, a milder cause of Coffin-Siris Syndrome? Broadening the phenotype with 17 additional individuals. American journal of medical genetics. Part A 6 38243407
2023 miR-29a-5p regulates the malignant biological process of liver cancer cells through ARID2 regulation of EMT. Advances in clinical and experimental medicine : official organ Wroclaw Medical University 5 36530029
2015 Clinicopathological and Targeted Exome Gene Features of a Patient with Metastatic Acinic Cell Carcinoma of the Parotid Gland Harboring an ARID2 Nonsense Mutation and CDKN2A/B Deletion. Case reports in oncological medicine 5 26634163
2025 ARID2-related disorder: further delineation of the clinical phenotype of 27 novel individuals and description of an epigenetic signature. European journal of human genetics : EJHG 4 40044822
2017 Analysis of ARID2 Gene Mutation in Oral Squamous Cell Carcinoma. Asian Pacific journal of cancer prevention : APJCP 4 29072391
2023 Early progression and transformation of a splenic diffuse red pulp small B-cell lymphoma with NOTCH1, ARID2, CREBBP, and TNFRSF14 gene mutations. Leukemia research reports 3 37664441
2022 Arid2-IR downregulates miR-132-3p through methylation to promote LPS-induced ALI in pneumonia. Inhalation toxicology 3 36074605
2018 Sequential backbone resonance assignment of AT-rich interaction domain of human BAF200. Biomolecular NMR assignments 2 30535613
2024 ARID2 Deficiency Enhances Tumor Progression via ERBB3 Signaling in TFE3-Rearranged Renal Cell Carcinoma. Current issues in molecular biology 1 39727945
2016 [The regulation of CD44 expression by new tumor suppressor gene Arid2 and the influence of Arid2 on the invasion and metastasis in hepatocellular carcinoma cells]. Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology 1 27095763
2026 Targeting the STK39/ARID2 Axis to Inhibit NF-κB Signaling: A Novel Pathway for Mesenchymal Stem Cell Osteogenic Differentiation in Osteoporosis Management. Journal of musculoskeletal & neuronal interactions 0 41764760
2026 A novel variant in ARID2 causes Coffin-Siris syndrome 6 with liver cirrhosis. Gene 0 41765118
2026 [Retracted] MicroRNA‑155 promotes tumor growth of human hepatocellular carcinoma by targeting ARID2. International journal of oncology 0 42028735
2025 Arid2 promotes Follicular B-cell differentiation and antibody responses in vivo. bioRxiv : the preprint server for biology 0 41256460
2024 Revealing the clinical impact of MTOR and ARID2 gene mutations on MALT lymphoma of the alimentary canal using targeted sequencing. Diagnostic pathology 0 39054516
2021 Frameshift Variant in ARID2 in a Chilean Individual with Coffin-Siris Syndrome Phenotype. Journal of pediatric genetics 0 38721575